Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2)

BACKGROUND: This AMEERA-2 study evaluated the pharmacokinetics, efficacy, and safety of the oral selective estrogen receptor degrader amcenestrant as a monotherapy with dose escalation in Japanese postmenopausal women with advanced estrogen receptor-positive and human epidermal growth factor recepto...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Kenji, Mukohara, Toru, Yonemori, Kan, Kawabata, Yumiko, Nicolas, Xavier, Tanaka, Tomoyuki, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119216/
https://www.ncbi.nlm.nih.gov/pubmed/36977973
http://dx.doi.org/10.1007/s12282-023-01443-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10119216/
https://www.ncbi.nlm.nih.gov/pubmed/36977973
http://dx.doi.org/10.1007/s12282-023-01443-8

Ejemplares similares